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Background: In Rwanda tuberculosis (TB) is one of the major health problems. To contribute to an improved
performance of the Rwandan National TB Control Program, we conducted a study with the following objectives:
(1) to assess the completion rate of sputum smear examinations at the end of the intensive phase of TB treatment;
(2) to assess the sputum conversion rate (SCR); (3) to assess associations between smear completion rate or SCR
with key health facility characteristics.
Methods: TB registers in 89 health facilities in five provinces were reviewed. Data of new and retreatment smear-
positive pulmonary TB (PTB+) cases registered between January and June 2006 were included in the study. Data on
key characteristics of the selected health facilities were also collected.
Results: Among 1509 new PTB + cases, 32 (2.1%) had died by 2 months, and 178 (11.8%) had been transferred-out.
Among the remaining 1299 patients, a smear examination at month 2 was done in 1039 (smear completion rate
80.0%). Among these 1039, 852 (82.0%) had become smear-negative. The smear completion rate and SCR varied
considerably between health facilities. A high number of new PTB cases at a health facility was the only significant
predictor of a low completion rate, while the only independent factor associated with low sputum conversion rates
was rural (vs. urban) location of the health facility.
Conclusions: In Rwanda, too few patients get a smear examination after 2 months of TB treatment; the SCR
among those with smear results was adequate at 82%. A high number of new TB patients at a health facility was a
significant predictor of a low completion rate. The national TB control program should design strategies to improve
completion rates.
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A third of the world’s population is infected by Mycobac-
terium tuberculosis and it is estimated by the World
Health Organization (WHO) that 1.45 million people
die each year from tuberculosis (TB) [1]. Ninety-five per-
cent of TB cases and 98% of TB deaths occur in devel-
oping counties [2]. In Rwanda TB is a major health
problem: in 2010 the TB notification rate was 72 per
100,000 population [3].
The sputum conversion rate (SCR) is the percentage
of smear-positive pulmonary TB (PTB+) cases registered* Correspondence: fkaigamba@gmail.com
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distribution, and reproduction in any mediumin a specified period that converted to smear negative
status after the standard two months of the intensive
phase of treatment. WHO recommends its use as a use-
ful indicator for TB control programs in monitoring the
TB program performance, and as a trigger for rigorous
assessment in patients with still positive smears [4]. Even
in well functioning national TB programs 25% of initially
PTB+ patients may still be smear-positive at the end of
the intensive phase of treatment, despite good adherence
and supervised medication [5].
Once the sputum smear has become negative, patients
are considered to be no longer infectious [6]. Those fail-
ing to achieve sputum conversion after 2 months are
more likely to have poor treatment outcomes [7-10]. Iftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ment, the intensive phase is extended for one more
month [5,11].
Studies to evaluate the SCRs and the predictive factors
for failure to convert have been conducted in several
countries in sub-Saharan Africa and elsewhere, but not
in Rwanda [7-10,12-23].
The objectives of this study were to assess the propor-
tion of patients in Rwandan health facilities for whom a
smear examination after the intensive phase of treatment
was done (completion rate), to assess the sputum smear
conversion rate among new cases and retreatment PTB+
cases, and to assess whether key health facility charac-
teristics are associated with smear completion rate or
with SCR in the Rwandan program.
Methods
Procedures
We conducted a review of TB treatment registers in
health facilities. The diagnosis of PTB in Rwanda is
mainly by sputum microscopy. The Kinyoun staining
technique was used during the study period (in 2009
Ziehl-Neelsen staining was adopted). All patients attend-
ing out-patient departments with cough for three weeks
or longer, were considered TB suspects and requested to
submit three sputum samples for microscopic examin-
ation (usually on two consecutive days). At least two
positive smears were required to confirm a suspected
TB case as PTB+ [24] (in 2009 guidelines were changed
to two weeks of cough and at least one positive smear)
[11].
Treatment Regimen
In Rwanda, TB treatment is directly supervised. The treat-
ment regimen for new PTB+ cases in Rwanda consists of
a two month intensive phase with a daily dose of fixed-
dose combination tablets containing Rifampicin (R), Iso-
niazid (H), Pyrazinamide (Z) and Ethambutol (E), followed
by a four months continuation phase of daily RH. To as-
sess sputum conversion, sputum microscopy is done after
the second (C2), fourth and sixth month of treatment.
PTB+ cases are expected to convert to negative sputum
status after two months of intensive TB treatment.
TB retreatment cases include cases that relapsed after,
defaulted during or failed on first line treatment. These
are treated with an eight-month regimen consisting of
daily streptomycin (S) and RHZE for two months, daily
RHZE for one month, and daily RHE for five months.
Sputum microscopy to assess conversion is done after
3 months of intensive treatment [11].
Study setting
To achieve representativeness for Rwanda, this study
was performed in three administrative districts selectedfrom each of the five provinces. Kigali city has three dis-
tricts while the other four provinces have more. All three
Kigali city districts were included in the study while the
three districts with the highest numbers of patients re-
gistered during the period we studied were selected from
each of the other four provinces. All TB diagnostic
health facilities (n = 89) in the selected 15 districts were
included in the study.Data collection and management
At each selected health facility aggregated data of TB
patients registered during the study period (January-June
2006) were abstracted. Data included the numbers of
patients whose sputum was not evaluated, who con-
verted to negative sputum status, who did not convert,
who died, who were lost to follow-up or were trans-
ferred out; data for new PTB+ cases and smear positive
retreatment cases were recorded separately. The PTB
patients in this study form around 70% of new smear-
positive PTB cases and about 75% of re-smear-positive
PTB treatment cases diagnosed nation-wide in the study
period.
Additionally data on health facility characteristics were
collected through structured interviews with the heads
of the health facilities: the type (hospital/health centre),
the location (urban/rural), the ownership status (private,
mission, government), the highest level of health care
workers in the TB department, and the date of the most
recent on-the-job training for staff in the TB depart-
ment. The educational levels of health care workers
included university graduate (grade A0), registered nurse
(grade A1), ordinary nurse (grade A2), and auxiliary
nurse (grade A3). Refresher training courses on TB clin-
ical care were considered as on-the-job-training.
Data entry was done with EpiInfo version 3.3 (CDC,
Atlanta, USA) and analysis with Stata 11 (StataCorp,
College Station, Texas, USA).Statistical Analysis
The coverage of sputum microscopy for PTB+ cases at
the end of the 2-month intensive phase (smear comple-
tion rate) was calculated as follows. The denominator
was the number of new PTB+ cases initially registered
minus those who had died or had been transferred out
during the first two months of treatment. The numer-
ator was the number of new PTB+ cases in whom a spu-
tum examination at C2 was done [10]. The SCR was
calculated as the proportion of patients who had become
smear-negative out of all patients of whom a 2-month
sputum smear was available [8-10,15,21,25]. Thus, the
SCR can vary between 0 and 1. Smear completion rate
and SCR were calculated similarly for retreatment cases,
except that the period between start of treatment and
Kayigamba et al. BMC Research Notes 2012, 5:357 Page 3 of 7
http://www.biomedcentral.com/1756-0500/5/357expected smear examination was three rather than two
months.
Because the distributions of smear completion rates
and SCRs were non-normal and logit transformation
could not redress this, linear regression with smear com-
pletion and SCR as outcomes was not done. Instead cat-
egorical variables were created based on cut-offs of
completion rate and SCR. A completion rate of less than
90% in a health facility was regarded as a poor comple-
tion rate. An SCR of less than 75% was regarded as a
low SCR [5]. Logistic regression analyses were done to
assess the associations between health facility character-
istics and low smear completion rate and low SCR. The
natural logarithm of the total number of new TB
patients in each health facility was used as a weight in
the regression analyses, giving more weight to health fa-
cilities with more patients. Odds ratios were derived
with 95% confidence intervals and P values of <0.05
were considered statistically significant.
Ethics
The Rwanda National TB Control Program (PNILT)
approved this study. All heads of selected health facilities
agreed to participate. Informed consent of patients was
not sought, as we collected and analysed anonymised
aggregated routine program data.
Results
New cases
The total number of registered new PTB+ cases between
January and June 2006 in the 89 health facilities was
1509. Overall 1039 (69%) of the 1509 new PTB+ cases
had sputum microscopy done after two months of inten-
sive phase treatment (Table 1). As smear results were
not expected from patients who had died (n = 32) or
who had transferred out to another clinic (n = 178), theTable 1 Sputum conversion rate against sputum completion r
Total number of patients
No sputum examination expected after intensive phase
Died< 2 months
Transferred out< 2 months
Sputum examination expected after intensive phase
Sputum smear done
Sputum smear not done
Sputum smear done after intensive phase
Sputum smear negative
Sputum smear positive
a Duration of intensive phase is 2 months.
b Duration of intensive phase is 3 months.completion rate was 80.0% (1039/1299); this varied be-
tween 17.6% and 100% per health facility (median
90.6%). Thirty-three sites had 100% coverage.
Sputum conversion was observed in 82.0% (852/1039)
of the patients. The SCR among new PTB+ cases varied
per health centre between 0 and 100% with a median of
84.0% (IQR 67.9-95.9%). At 21 sites all examined cases
had converted.
Figure 1 shows the variation of completion rate and
SCR in all health facilities. Health facilities that per-
formed well on one indicator did not necessarily per-
form well on the other indicator.
Retreatment cases
The total number of smear-positive retreatment patients
was 206. After the three months intensive phase, a spu-
tum smear was available for 133 out of the 176 in whom
it should have been done (completion rate 75.6%). Smear
conversion was observed in 109 (82.0%); 24 had not con-
verted (Table 1).
Health facilities
Out of the 89 health facilities included in the study, 70
(78.7%) were health centres and 19 (21.3%) were hospi-
tals. The number of newly registered PTB+ cases per
health facility in the six-month period varied between 0
and 71 (median 8). One site did not have any new cases
and was excluded from further analyses. The number of
registered retreatment cases varied between 0 and 29
(median 1). Forty-one sites did not register any retreat-
ment cases in the study period.
Analysis of associations between health facility attributes
and completion rate among new cases
Forty-three (48.9%) health facilities had completion rates







32 (15.2%) 5 (16.7%)
178 (84.8%) 25 (83.3%)
1299 176
1039 (80.0%) 133 (75.6%)
260 (20.0%) 43 (24.4%)
1039 133
852 (82.0%) 109 (82.0%)
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Figure 1 Sputum conversion rate against sputum completion rate among new TB cases for 89 health facilities. The size of the circles is
proportional to the number of new TB cases diagnosed at each of the 89 health facilities in Rwanda. The horizontal line at 0.75 indicates the
cut-off for an adequate sputum conversion rate. The vertical line at 0.9 indicates the cut-off for an adequate smear completion rate.
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centre) (p = 0.025), urban location of facility (p = 0.008),
the province (p = 0.045), and the number of new patients
diagnosed at the centre (p = 0.001) (Table 2). In multi-
variable logistic regression, the only significant predictor
of a low completion rate was a high number (≥15) of
new PTB cases at the health facility.
Analysis of associations between health facility attributes
and SCR among new cases
Twenty-eight (31.8%) of health facilities had smear con-
version rates below 75%. In bivariable analysis hospitals
(versus health centres) and urban health facilities (versus
rural health facilities) were less likely to have low SCR
(p = 0.017 and p = 0.001, respectively; Table 3). In multi-
variable logistic regression the only independent factor
associated with a low SCR was rural location of the
health facility (p = 0.001).
Discussion
The SCR among new PTB+ cases after the intensive
phase of treatment was 82% among both new and
retreatment cases. The WHO standard for a well func-
tioning national TB program is a conversion rate of at
least 75% among new PTB+ [5], so the Rwandan pro-
gram appears to be performing well in this respect.
Comparisons of SCR between studies are challenging be-
cause different researchers have used different definitions
of SCR. Some include all newly diagnosed smear-positive
PTB patients in the denominator [18-20], while others
only include those of whom a smear result was availableafter the intensive phase of treatment [7-9,15,21,25]. The
first approach can yield a relatively low SCR if the pro-
gram is not successful in performing smears after the in-
tensive phase; in those cases the SCR becomes hard to
interpret. Therefore we opted to calculate both a smear
completion rate (reflecting the ability of the program to
get sputum smears done) and the SCR (reflecting the
ability of treatment to sterilise the sputum).
The SCR among new PTB patients in our study is
lower than those found in studies performed in Tanzania
(98.6%) [21], China (95.0%) [8], Cameroon (86.6%) [9],
but higher than in a refugee camp in Thailand (75.0%)
[7] and Taiwan (80.0%) [25]. The SCR is similar to that
observed in Burkina Faso (92.1%) [10] and Uganda
(76.0%) [15].
A number of studies examined patient level factors
in relation to sputum conversion. Important factors
were shown to be higher pre-treatment sputum grade
[9,15-17,19,22,23] and extensive disease involvement
on chest X-Ray [19,20]. Some studies found that older
age [9,16,19] and male sex [10,18,21] were related to fail-
ure to convert. The effect of initial drug resistance on spu-
tum conversion differed between studies [13,15,16,22,23]
Co-infection with HIV has not been reported to be a sig-
nificant factor for SCR or time to conversion [14-16,21,23].
So, individual patient level factors are important deter-
minants of SCR. However in our study, we examined
whether health facility factors were associated with SCR,
using aggregate data. Sputum conversion was significantly
associated with the location of the health facility at
which patients were treated: urban sites more often had
Table 2 Associations between poor sputum completion rates among new sputum-smear positive PTB patients and
health facility characteristics at 88 health facilities, Rwanda, 2006





95%CI P b Multi-variable
Odds Ratio a
95%CI P b
Overall 88 (100%) 43 (48.9%)
Category of health facility 0.025
Health centre 69 (78.4%) 30 (43.5%) 1
Hospital 19 (21.6%) 13 (68.4%) 2.0 1.1-3.7
Location of health facility 0.008
Rural 60 (68.2%) 25 (41.7%) 1
Urban 28 (31.8%) 18 (64.3%) 2.1 1.2-3.8
Health facility status 0.311
Mission/private 40 (45.5%) 19 (47.5%) 1
Public 48 (54.5%) 24 (50.0%) 1.3 0.8-2.3
Most recent on-the-job training
for TB staff
Before 2006 or none at all 47 (53.4%) 22 (46.8%) 1 0.643
2006 41 (46.6%) 21 (51.2%) 1.1 0.7-2.0
Location of facilities (Province) 0.045
East 13 (14.8%) 8 (61.5%) 1
Kigali 17 (19.3%) 11 (64.7%) 1.4 0.6-3.6
North 18 (20.5%) 4 (22.2%) 0.4 0.1-1.0
West 22 (25.0%) 11 (50.0%) 0.9 0.3-2.2
South 18 (20.5%) 9 (50.0%) 1.0 0.4-2.5
Number of new PTB cases in
6-month period
0.001 0.001
1-5 32 (36.4%) 9 (28.1%) 1 1
6-14 27 (30.7%) 14 (51.9%) 2.0 0.9-4.4 2.0 0.9-4.4
≥15 29 (33.0%) 20 (69.0%) 4.1 1.9-8.8 4.1 1.9-8.8
a. The natural log of the number of newly registered PTB cases was used as weight in the regression analysis; b Based on the log likelihood ratio. One site did not
register any new cases during the study period and was not included in the results in this table. PTB pulmonary tuberculosis; TB tuberculosis; CI confidence
interval; HCW health care worker.
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be proximity and lower travel cost [26-28]. Lower socio-
economic status [27-29], illiteracy or insufficient know-
ledge about TB disease [28-30] are more frequent in
rural areas. Although quality control for smear micros-
copy is done by the National Reference Laboratory, it is
possible that the variation in SCR between centres is
caused by varying quality of the reading of smears.
Failure to become smear-negative might be due to
(multi-) drug-resistant TB [22]. In Rwanda a national
representative study conducted in 2004–5 estimated a
prevalence of 3.9% of MDR among new smear-positive
PTB patients [31]. This is a relatively high prevalence,
but too low to significantly impact on the SCR in
Rwanda.
The completion rate of sputum smear examinations
after the intensive phase of treatment was 80%, which islow. Health facilities with a high number of new TB
patients were more likely to have a low completion rate;
this can be attributed to heavy workload in facilities that
are under-staffed. District hospitals in Rwanda serve as
referral facilities for all satellite diagnostic and treatment
centres in their respective catchment zones. In addition
to receiving many patients in routine care, these hospi-
tals receive complicated clinical cases from health cen-
tres, including TB cases; this makes the workload
heavier. Although our study did not find significant asso-
ciations between level of education of health staff and
completion rates, upgrading the level of education for
existing staff or additional recruitments of some A1 staff
at health facilities may improve smear completion rates
and other standards of care. The majority of health facil-
ity staff did not get regular technical supervision or
regular on-the-job training for TB management. Results
Table 3 Associations between poor sputum smear conversion rates among new sputum-smear positive PTB patients
and health facility characteristics in 88 health facilities, Rwanda, 2006






95%CI P b Multi-variable
Odds Ratio a
95%CI P b
Overall 88 (100%) 28 (31.8%)
Category of health facility 0.017
Health centre 69 (78.4%) 24 (34.8%) 1
Hospital 19 (21.6%) 4 (21.1%) 0.4 0.2-0.9
Location of health facility 0.001 0.001
Rural 60 (68.2%) 23 (38.3%) 1 1
Urban 28 (31.8%) 5 (17.9%) 0.3 0.2-0.6 0.3 0.2-0.6
Health facility status 0.216
Mission/private 40 (45.5%) 13 (32.5%) 1
Public 48 (54.5%) 15 (31.3%) 0.7 0.4-1.2
Most recent on-the-job
training for TB staff
Before 2006 or none at all 47 (53.4%) 15 (31.9%) 1 0.235
2006 41 (46.6%) 13 (31.7%) 1.4 0.8-2.6
Location of facilities (Province) 0.729
East 13 (14.8%) 4 (30.8%) 1
Kigali 17 (19.3%) 4 (23.5%) 0.6 0.2-1.7
North 18 (20.5%) 8 (44.4%) 1.0 0.4-2.9
West 22 (25.0%) 7 (31.8%) 1.1 0.4-2.9
South 18 (20.5%) 5 (27.8%) 0.9 0.3-2.4
Number of new PTB cases in
6-month period
0.499
1-5 32 (36.4%) 11 (34.4%) 1
6-14 27 (30.7%) 9 (33.3%) 1 0.4-2.2
≥15 29 (33.0%) 8 (27.6%) 0.7 0.3-1.5
The data in this table are based on new sputum smear positive patients of whom a control sputum smear was available after 2 months of intensive treatment.
One site did not register any new cases during the study period and was not included in the results in this table. a The natural log of the number of newly
registered PTB cases was used as weight in the regression analysis. b Based on the log likelihood ratio. PTB pulmonary tuberculosis; TB tuberculosis; CI confidence
interval; HCW health care worker.
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health care workers. Health facilities that showed a high
smear completion rate did not necessarily have a high
conversion rate and vice versa; very few clinics had low
rates on both measures. These measures are influenced
by different health care factors: the smear completion
rate can be influenced by quality of the work of the clin-
ical staff, and the conversion rate by the quality of the la-
boratory work.
This study has some limitations. The data were col-
lected in 2006 and possibly smear completion rate has
improved since then. The sample size of this study was
limited, although this was a representative sample of all
health facilities diagnosing and treating TB, the power to
detect significant associations was limited. Error in com-
pleting records may not be uncommon in routine clinicsand may have led to bias in data collection. Individual
patient factors like age, sex, smear grade and adherence
are –or may be- related to smear conversion; this study
focused on health sector factors, and thus omitted
knowingly important factors from the analysis.Conclusions
In Rwanda the coverage of smear sputum examination
after the end of the intensive phase of TB treatment is
too low and efforts are needed to increase this. The SCR
in Rwanda at 82% is adequate. A high number of new
TB patients at a health facility was a significant predictor
of a low completion rate. The national TB control pro-
gram should design strategies to improve completion
rates, with a focus on the busiest clinics.
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